A prospective study to evaluate the effectiveness of positron emission mammography (PEM) in predicting the treatment outcome of chemotherapy in patients with breast cancer.
Not Applicable
- Conditions
- brast cancer
- Registration Number
- JPRN-UMIN000009314
- Lead Sponsor
- Department of Radiology, Graduate School of Medicine, Yokohama City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.Pregnant and possibly pregnant women 2.Other patients determined to be inappropriate by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The evaluation of FDG uptake.
- Secondary Outcome Measures
Name Time Method The correlation of FDG uptake with treatment outcome and prognosis.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does PEM metabolic imaging correlate with HER2-positive and triple-negative breast cancer subtypes in predicting chemotherapy response?
What is the predictive accuracy of PEM compared to PET-CT in assessing chemotherapy outcomes for breast cancer patients?
Which biomarkers like Ki-67 or ER/PR are linked to PEM metabolic changes in breast cancer patients during chemotherapy?
What safety profiles and radiation exposure management strategies are reported in the JPRN-UMIN000009314 PEM trial by Yokohama City University?
How does integrating PEM with other imaging modalities improve chemotherapy outcome prediction in breast cancer?